Literature DB >> 390084

Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein.

E H Beachey, G H Stollerman, R H Johnson, I Ofek, A L Bisno.   

Abstract

We tested the ability of pepsin-extracted, highly purified M protein to induce type-specific immunity in experimental animals and humans. M protein was prepared from limited peptic digests of whole group A type 24 streptococci and was purified to chemical homogeneity as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, quantitative amino acid analysis, and Edman degradation. For vaccination, the lyophilized M24 protein preparation (pep M24) was precipitated in aluminum hydroxide. When injected into laboratory animals, alum-precipitated pep M24 produced type-specific protective antibodies and was free of non-type-specific immunoreactivity. In man, skin tests with 1-microgram doses of pep M24 were negative in all 37 adults tested. 12 adult human volunteers received two-four subcutaneous injections of 100-200 micrograms of alum-precipitated pep M24 at intervals of at least 2 wk. The immune response to pep M24 was measured by a variety of assays designed to detect (a) type-specific humoral antibodies (opsonophagocytic, long chain, and mouse protection tests); (b) total humoral antibodies (complement fixation and enzyme-linked immunosorbent assay); (c) cellular immunity (skin tests); and (d) heart cross-reactive antibodies (immunofluorescence). Type-specific opsonic antibodies developed in 10 of the 12 vaccinees, and positive delayed-type skin tests developed in 11. Immune sera from two of the vaccinees were effective in mouse-protection tests against challenge with M24 but not M6 streptococci. None of the volunteers developed heart-reactive antibodies or antibodies to non-type-specific M protein antigens. Alum-precipitated pep M24 was well-tolerated in man, and no serious local or systemic reactions were observed. Thus, pep M24 induces type-specific, protective antibodies in doses that are well-tolerated in man.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 390084      PMCID: PMC2185669          DOI: 10.1084/jem.150.4.862

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  The relative rheumatogenicity of strains of group A streptococci.

Authors:  G H Stollerman
Journal:  Mod Concepts Cardiovasc Dis       Date:  1975-07

2.  Separation of the type specific M protein from toxic cross reactive antigens of group A streptococci.

Authors:  E H Beachey; E Y Chiang; J M Seyer; A H Kang; T M Chiang; G H Stollerman
Journal:  Trans Assoc Am Physicians       Date:  1977

3.  Repeating covalent structure of streptococcal M protein.

Authors:  E H Beachey; J M Seyer; A H Kang
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

4.  Characterization of a non-type-specific antigen(s) associated with group A streptococcal type 12 M protein.

Authors:  K L Vosti
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

5.  Streptococcal M protein extracted by nonionic detergent. II. Analysis of the antibody response to the multiple antigenic determinants of the M-protein molecule.

Authors:  V A Fischetti
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

6.  Enzyme-linked immunosorbent assay for streptococcal M protein antibodies.

Authors:  H Russell; R R Facklam; L R Edwards
Journal:  J Clin Microbiol       Date:  1976-05       Impact factor: 5.948

7.  Basophils in tuberculin and "Jones-Mote" delayed reactions of humans.

Authors:  P W Askenase; J E Atwood
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

8.  Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus.

Authors:  R D'Alessandri; G Plotkin; R M Kluge; M K Wittner; E N Fox; A Dorfman; R H Waldman
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

9.  Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen.

Authors:  I van de Rijn; J B Zabriskie; M McCarty
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

10.  Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen.

Authors:  E H Beachey; G H Stollerman; E Y Chiang; T M Chiang; J M Seyer; A H Kang
Journal:  J Exp Med       Date:  1977-06-01       Impact factor: 14.307

View more
  21 in total

Review 1.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

3.  Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.

Authors:  Hae-Sun Park; P Patrick Cleary
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Expression of protective and cardiac tissue cross-reactive epitopes of type 5 streptococcal M protein in Escherichia coli.

Authors:  T P Poirier; M A Kehoe; J B Dale; K N Timmis; E H Beachey
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

5.  Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.

Authors:  Jay A Spencer; Tom Penfound; Sanaz Salehi; Michelle P Aranha; Lauren E Wade; Rupesh Agarwal; Jeremy C Smith; James B Dale; Jerome Baudry
Journal:  Vaccine       Date:  2021-02-26       Impact factor: 3.641

6.  Biochemical and biological properties of the binding of human fibrinogen to M protein in group A streptococci.

Authors:  E Whitnack; E H Beachey
Journal:  J Bacteriol       Date:  1985-10       Impact factor: 3.490

Review 7.  Immunopathogenesis of rheumatic fever and rheumatic heart disease-current concepts.

Authors:  K S Reddy; P S Rao; M L Bhatia
Journal:  Indian J Pediatr       Date:  1982 Nov-Dec       Impact factor: 1.967

8.  Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein.

Authors:  E H Beachey; A Tartar; J M Seyer; L Chedid
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  Induction of human gamma interferon by structurally defined polypeptide fragments of group A streptococcal M protein.

Authors:  D A Weigent; E H Beachey; T Huff; J W Peterson; G J Stanton; S Baron
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

10.  Temporal relationship of cytokine release by peripheral blood mononuclear cells stimulated by the streptococcal superantigen pep M5.

Authors:  M Kotb; H Ohnishi; G Majumdar; S Hackett; A Bryant; G Higgins; D Stevens
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.